Drug Trial Radar · NCT06478706
A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Jun 26, 2024
Primary completion
Nov 14, 2025
Study completion Nov 14, 2025
Sponsor
- Lead sponsor
- Enterprise Therapeutics LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is the first to give ETD001 to people with CF. The study will be run in two parts. Part A will assess if ETD001 is safe to give to people with CF, and Part B will assess if ETD001 improves lung function. The study drug is taken twice a day, in Part A it is taken for 7 days and in Part B for 28 days. In Part B there will be a separate period where dummy medicine is given for 28 days so the treatments can be compared. In Part A participants will receive 13 doses of either ETD001 or placebo, 8 people will take part. Participants will take up to 56 days to finish the study and make 5 outpatient visits. In Part B participants will receive 55 doses of ETD001 and 55 doses of placebo, 32 people will take part. Participants will take up to 140 days to finish the study and will make 8 outpatient visits. Study assessments include physical examinations, vital signs, heart traces, blood/urine samples, breathing tests and health questionnaires.
Conditions
- Cystic Fibrosis
Interventions
ETD001Drug
Twice daily doses
PlaceboDrug
Twice daily doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and tolerability of repeat inhaled doses of ETD001 monitored by assessment of adverse eventsTime frame: 28 days
- Part B: Effect of repeat inhaled doses of ETD001 on percent predicted forced expiratory volume in 1 second (ppFEV1)Time frame: Treatment Period 1 & 2 - Day 1 (pre-dose, 1, 2 & 4 hours post dose), Day 14 (pre-dose, 1 & 2 hours post), Day 28 (at 0, 1, 2 & 4 hours post dose)
Locations
21 sites in 4 countries. Site status is shown where the registry gives one.
Hospices Civils de Lyon
Lyon, France
CHU de Montpellier
Montpellier, France
Hôpital Cochin
Paris, France
Hôpitaux de Toulouse
Toulouse, France
Charité Universtaetsmedizin
Berlin, Germany
CF-Studienzentrum Universitätsklinikum Köln
Cologne, Germany
Westdeutsches Lungenzentrum am Universitätsklinikum
Essen, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
IKF Pneumologie
Frankfurt, Germany
LMU Kinikum
Munich, Germany
Azienda Ospedaliera Universitaria Meyer
Florence, Italy
IRCCS Istituto Giannina Gaslini
Genova, Italy
Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico
Milan, Italy
Ospedale Pediatrico Bambino Gesù
Roma, Italy
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Italy
Belfast Health and Social Care Trust
Belfast, United Kingdom
Royal Papworth Hospital
Cambridge, United Kingdom
All Wales Adult CF Centre
Cardiff, United Kingdom
Queen Elizabeth University Hospital West of Scotland CF Service
Glasgow, United Kingdom
Royal Brompton Hospital
London, United Kingdom
Southampton General Hospital
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.